Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biocon
Pharma
BIO-WuXi, Takeda, FDA-Carvykti—Fierce Pharma Asia
WuXi AppTec left BIO amid alleged biosecurity concerns. Takeda will close a gene therapy plant. The FDA flagged early deaths in a Carvykti trial.
Angus Liu
Mar 15, 2024 10:15am
Biocon sells insulin and other brands to Eris for $150M
Mar 14, 2024 11:34am
BeiGene, BMS, AZ-FibroGen and more—Fierce Pharma Asia
Mar 1, 2024 8:55am
FTC takes patent scrutiny to Sanofi, Mylan's insulin case
Nov 21, 2023 11:34am
Capturing COVID: Biopharma through the lens during the pandemic
Nov 13, 2023 7:45am
FDA hits Biocon's insulin copycat with a CRL
Oct 9, 2023 11:53am